Hims & Hers Health (NYSE:HIMS) Reaches New 52-Week High at $21.16

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) reached a new 52-week high during trading on Thursday . The company traded as high as $21.16 and last traded at $20.59, with a volume of 3031408 shares. The stock had previously closed at $19.58.

Analyst Ratings Changes

A number of brokerages have recently issued reports on HIMS. Canaccord Genuity Group upped their price objective on shares of Hims & Hers Health from $20.00 to $24.00 and gave the company a “buy” rating in a research note on Wednesday, May 22nd. Piper Sandler upped their price objective on shares of Hims & Hers Health from $11.00 to $13.00 and gave the company a “neutral” rating in a research note on Tuesday, May 7th. Truist Financial upped their price objective on shares of Hims & Hers Health from $10.00 to $13.00 and gave the company a “hold” rating in a research note on Tuesday, February 27th. Imperial Capital raised shares of Hims & Hers Health from an “in-line” rating to an “outperform” rating and set a $16.00 price objective for the company in a research note on Wednesday, February 28th. Finally, Jefferies Financial Group reissued a “hold” rating and set a $15.00 price target (down previously from $17.00) on shares of Hims & Hers Health in a research report on Tuesday, April 16th. Seven analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, Hims & Hers Health presently has a consensus rating of “Moderate Buy” and an average price target of $15.69.

Hims & Hers Health Stock Performance

The company’s 50-day moving average is $14.31 and its 200 day moving average is $11.39.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, May 6th. The company reported $0.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.03. The firm had revenue of $278.20 million for the quarter, compared to the consensus estimate of $270.37 million. Hims & Hers Health had a negative net margin of 0.24% and a negative return on equity of 0.70%. The business’s quarterly revenue was up 45.8% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.05) EPS. As a group, equities analysts predict that Hims & Hers Health, Inc. will post 0.18 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Andrew Dudum sold 50,361 shares of the firm’s stock in a transaction that occurred on Wednesday, March 20th. The shares were sold at an average price of $16.34, for a total value of $822,898.74. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other Hims & Hers Health news, insider Soleil Boughton sold 63,621 shares of the firm’s stock in a transaction that occurred on Wednesday, March 13th. The shares were sold at an average price of $15.17, for a total transaction of $965,130.57. Following the sale, the insider now owns 154,345 shares in the company, valued at approximately $2,341,413.65. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Andrew Dudum sold 50,361 shares of the firm’s stock in a transaction that occurred on Wednesday, March 20th. The stock was sold at an average price of $16.34, for a total transaction of $822,898.74. The disclosure for this sale can be found here. Insiders have sold a total of 594,308 shares of company stock valued at $8,464,914 in the last 90 days. 17.71% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Hims & Hers Health

Several institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. increased its position in Hims & Hers Health by 1.0% in the first quarter. Vanguard Group Inc. now owns 14,310,192 shares of the company’s stock worth $221,379,000 after purchasing an additional 136,907 shares during the last quarter. Forerunner Ventures Management LLC purchased a new position in Hims & Hers Health during the fourth quarter worth $86,836,000. Dimensional Fund Advisors LP boosted its stake in Hims & Hers Health by 9.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,147,927 shares of the company’s stock worth $19,117,000 after buying an additional 193,507 shares during the period. Farallon Capital Management LLC boosted its stake in Hims & Hers Health by 3,890.5% during the first quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock worth $25,928,000 after buying an additional 1,634,000 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its stake in Hims & Hers Health by 1.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,294,759 shares of the company’s stock worth $11,523,000 after buying an additional 22,009 shares during the period. Institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.